Tsinghua University

Gp Medical, Inc.

Industrial Technology Research Institute

Other

Kyungpook National University Industry-Academic Cooperation Foundation

Taimed Biologics, Inc.

Hsiang-Fa Liang

Hosheng Tu

Hsing-Wen Sung

Yu-Hsin Lin

Mei-Chin Chen

Maggie J M Lu

Li-Wen Chang

Ming-Cheng Wei

Ya-Chin Lo

James Nienyuan Chang

Jui-Hsiang Chen

In San Kim

Chih-Peng Liu

Chia-Mu Tu

Min-Ying Lin

Yi-Ju Ko

Byung Heon Lee

Yi-Ting Hsieh

Hsiang-Wen Tseng

Chun-Min Liu

Tse-Min Teng

Yi-ju Ko

Yi-Man Chou

Shing-Ming Cheng

Ting-Fan Yang

Meng-Hsin Chen

Chin-Tsung Huang

Kuei-Ling Kuo

An-Chieh Li

Maggie Jm Lu

Disclosed herein is a long acting pharmaceutical composition for treating or preventing human immunodeficiency virus (HIV) infection. The pharmaceutical composition comprises a suspension of a lysine-based aspartyl protease inhibitor or salt thereof, a surface modifier, and a pharmaceutically acceptable carrier; wherein the lysine-based aspartyl protease inhibitor or salt thereof has an average effective particle size of less than about 500 nm. A method for treating or preventing HIV infection with the pharmaceutical composition is also disclosed.

Long acting pharmaceutical composition of protease inhibitor

The present invention relates to a target-aiming drug delivery system for diagnosis and treatment of cancer containing liposome labeled with peptides which specifically targets interleukin-4 receptors, and a manufacturing method thereof. The liposome which contains anticancer drugs labeled with IL4RPep peptides prepared in accordance with the present invention can deliver drugs to cancer cells in which IL-4 receptors are overexpressed by IL4RPep peptides which specifically bind to IL-4 receptors, and the drug delivery can recognize cancer cells specifically by a label. Thus, IL4RPep peptides can increase the effect of drugs only on cancer tissues and at the same time significantly reduce the side effects on normal tissues, which makes possible in vivo(molecular) imaging and early diagnosis of tumors. Therefore, the liposome which contains anticancer drugs labeled with IL4Pep peptides of the present invention can be applied, as the target-aiming drug delivery system, effectively to the diagnosis and treatment of cancers.

Target-aiming drug delivery system for diagnosis and treatment of cancer containing liposome labeled with peptides which specifically targets interleukin-4 receptors, and manufacturing method thereof

The disclosure provides a biomedical composition, including: a hyaluronic acid; a modified histidine; and a polymer or C-Calkane, wherein the modified histidine and the polymer or C-Calkane are grafted to at least one primary hydroxyl group of the hyaluronic acid to allow the hyaluronic acid to form a hyaluronic acid derivative, wherein a graft ratio of the modified histidine is about 1-100%, and a graft ratio of the polymer or C-Calkane is about 0-40%.

Biomedical composition

An isolated peptide including an amino acid sequence of SEQ ID NO: 1 is provided. The disclosure also provides a delivery system comprising a carrier having a surface, a drug or a dye encapsulated in the carrier, and the disclosed peptide (having an amino acid sequence of SEQ ID NO: 1) grafted on the surface of the carrier.

Peptide for transmigration across blood brain barrier and delivery systems comprising the same

The invention discloses the nanoparticles composed of chitosan, poly-&#x3b3;-glutamic acid, and at least one bioactive agent characterized with a positive surface charge and their enhanced permeability for paracellular drug delivery.

Nanoparticles for protein drug delivery

The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one protein drug or bioactive agent characterized with a positive surface charge and their enhanced permeability for paracellular protein drug and bioactive agent delivery.

The invention discloses the nanoparticles composed of &#x3b3;-PGA-PLA block copolymers conjugated with galactosamine as a potential drug delivery system for treating liver cancers.

Nanoparticles for targeting hepatoma cells

The nanoparticles composed of &#x3b3;-PGA-PLA block copolymers that are conjugated with galactosamine as a potential drug delivery system and loaded with anticancer drugs for treating liver cancers.

Growing community of inventors

Hsinchu, Taiwan

Hsiang-Fa Liang